ArticleProceedings of the National Academy of Sciences of the United States of America2018
C-terminal modification of the insulin B:11-23 peptide creates superagonists in mouse and human type 1 diabetes.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Hybrid Insulin Peptides as Antigens and Tolerogens for Pathogenic T Cells in Autoimmune Diabetes.Immunological reviews · 2026Review
- Beyond Sequence: Posttranslational Remodeling of Antigens in Autoimmunity.Immunological reviews · 2026Review
- Influence of Peptide Conjugation Sites on Lunatin-Alumina Nanoparticles: Implications for Membrane Interaction and Antimicrobial Activity.Pharmaceuticals (Basel, Switzerland) · 2025Article
- CD4Immunity · 2024Article
- Aire mediates tolerance to insulin through thymic trimming of high-affinity T cell clones.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma.Oncoimmunology · 2024Article
- Antigen-specific T cell responses in autoimmune diabetes.Frontiers in immunology · 2024Review
- Tracking DNA-based antigen-specific T cell receptors during progression to type 1 diabetes.Science advances · 2023Article
- A mutagenesis study of autoantigen optimization for potential T1D vaccine design.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes.Frontiers in immunology · 2023Article
- Determinants of tumor immune evasion: the role of T cell exposed motif frequency and mutant amino acid exposure.Frontiers in immunology · 2023Article
- Transcriptional re-programming of insulin B-chain epitope-specific T-follicular helper cells into anti-diabetogenic T-regulatory type-1 cells.Frontiers in immunology · 2023Article
- Posttranslational modifications in diabetes: Mechanisms and functions.Reviews in endocrine & metabolic disorders · 2022Review
- Temporal development of T cell receptor repertoires during childhood in health and disease.JCI insight · 2022Article
- A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- A Novel Tolerogenic Antibody Targeting Disulfide-Modified Autoantigen Effectively Prevents Type 1 Diabetes in NOD Mice.Frontiers in immunology · 2022Article
- Calcitonin gene-related peptide is a potential autoantigen for CD4 T cells in type 1 diabetes.Frontiers in immunology · 2022Article
- Know thy immune self and non-self: Proteomics informs on the expanse of self and non-self, and how and where they arise.Proteomics · 2021Review
- T cell receptor recognition of hybrid insulin peptides bound to HLA-DQ8.Nature communications · 2021Article
- T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
A polymorphism at β57 in some major histocompatibility complex class II (MHCII) alleles of rodents and humans is associated with a high risk for developing type 1 diabetes (T1D). However, a highly diabetogenic insulin B chain epitope within the B:9-23 peptide is presented poorly by these alleles to a variety of mouse and human CD4 T cells isolated from either nonobese diabetic (NOD) mice or humans with T1D. We have shown for both species that mutations at the C-terminal end of this epitope dramatically improve presentation to these T cells. Here we present the crystal structures of these mutated peptides bound to mouse IA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.